Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05082779 · ClinicalTrials.gov registry record · Phase 1
Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159
A Phase 1 study, sponsored by Cascade Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 79
- Enrollment target
NCT05082779 is a Phase 1 study that has completed, run by Cascade Pharmaceuticals. The registered enrollment target is 79 participants.
The verdict
NCT05082779, a Phase 1 study, has completed, sponsored by Cascade Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 79 participants
- Enrollment target
Study Summary
The whole study includes 2 parts. Both the SAD study and MAD study are randomized, double-blinded, and placebo-controlled studies, conducted in healthy subjects, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics profiles of CS0159. The SAD part also involves a pilot food effect (FE) study, designed to assess the food effect on single-dose PK profile in healthy subjects.
Interventions
- DRUG CS0159
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2021-10-26 |
| Est. Completion | 2022-10-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05082779
The ClinicalTrials.gov registry entry for NCT05082779 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cascade Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CS0159 is the first listed.
NCT05082779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05082779 about?
NCT05082779 is a clinical study titled "Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159". The whole study includes 2 parts. Both the SAD study and MAD study are randomized, double-blinded, and placebo-controlled studies, conducted in healthy subjects, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics profiles of CS0159. The SAD part also involves a pilot food eff...
What is the current status of trial NCT05082779?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 79 participants. The study started on 2021-10-26. Estimated completion is 2022-10-12.
What interventions are being tested in trial NCT05082779?
The interventions under investigation include: CS0159 (DRUG).
Who is sponsoring clinical trial NCT05082779?
This trial is sponsored by Cascade Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.